PhageNova Bio, Inc.
Biotechnology company developing ligand-directed, systemically administered gene delivery vectors based on an engineered bacteriophage/adeno-associated virus hybrid. The organization is advancing preclinical and IND-enabling studies, GMP manufacturing, and first-in-human clinical planning for oncology applications while also applying the platform to vaccine development and pulmonary delivery.
Industries
N/A
Nr. of Employees
small (1-50)
PhageNova Bio, Inc.
Thomas O. Daniel Research Incubator and Collaboration Center, 556 Morris Ave, S7-F3, Summit, NJ 07901
Products
PNB-001 (lead oncology development candidate)
Lead ligand-directed hybrid bacteriophage–AAV vector program targeting solid tumors; undergoing IND-enabling studies, toxicology, and GMP manufacturing preparatory to a Phase 1 clinical trial.
PNB-V01 (phage-based vaccine platform)
Platform for phage-based vaccines designed to display viral epitopes on capsid surfaces and to deliver antigen transgenes to lymphoid and pulmonary tissues, including aerosol formulations intended to be cold-chain independent.
PNB-001 (lead oncology development candidate)
Lead ligand-directed hybrid bacteriophage–AAV vector program targeting solid tumors; undergoing IND-enabling studies, toxicology, and GMP manufacturing preparatory to a Phase 1 clinical trial.
PNB-V01 (phage-based vaccine platform)
Platform for phage-based vaccines designed to display viral epitopes on capsid surfaces and to deliver antigen transgenes to lymphoid and pulmonary tissues, including aerosol formulations intended to be cold-chain independent.
Expertise Areas
- Targeted gene delivery
- Ligand discovery and targeting
- Preclinical development and toxicology
- GMP manufacturing and CMC
Key Technologies
- Hybrid bacteriophage–AAV vectors
- Ligand-directed targeting
- Transgene payload engineering
- Pulmonary/aerosol delivery formulations
News & Updates
Peer-reviewed publication describing design and development of phage-based COVID-19 vaccination strategies intended for cold-chain-independent distribution.
Publication detailing pulmonary vaccination using targeted phage display in preclinical models.
Protocol paper describing construction of targeted hybrid vectors for mammalian transduction (Nat Protoc. 2007).
Broad technology and intellectual property portfolio licensed from an academic cancer center covering core science behind lead constructs and platform.
Engaged a CDMO to support construct optimization and eventual GMP manufacturing.
Peer-reviewed publication describing design and development of phage-based COVID-19 vaccination strategies intended for cold-chain-independent distribution.
Publication detailing pulmonary vaccination using targeted phage display in preclinical models.
Protocol paper describing construction of targeted hybrid vectors for mammalian transduction (Nat Protoc. 2007).
Broad technology and intellectual property portfolio licensed from an academic cancer center covering core science behind lead constructs and platform.
Engaged a CDMO to support construct optimization and eventual GMP manufacturing.